Arcadia Investment Management Corp MI Raises Stake in Dyne Therapeutics, Inc. $DYN

Arcadia Investment Management Corp MI increased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 23.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,215 shares of the company’s stock after buying an additional 10,350 shares during the period. Arcadia Investment Management Corp MI’s holdings in Dyne Therapeutics were worth $526,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Arizona State Retirement System grew its stake in Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock worth $183,000 after acquiring an additional 1,481 shares during the period. Y Intercept Hong Kong Ltd boosted its holdings in shares of Dyne Therapeutics by 725.8% during the first quarter. Y Intercept Hong Kong Ltd now owns 80,665 shares of the company’s stock worth $844,000 after purchasing an additional 70,897 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Dyne Therapeutics by 22.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company’s stock worth $201,000 after purchasing an additional 3,496 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Dyne Therapeutics in the first quarter valued at $1,031,000. Finally, XTX Topco Ltd acquired a new position in Dyne Therapeutics in the first quarter valued at $330,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $18.79 on Friday. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The company has a market cap of $2.68 billion, a PE ratio of -4.87 and a beta of 1.16. The company’s fifty day simple moving average is $16.18 and its 200-day simple moving average is $13.03. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $31.32.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.05. As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, CEO John Cox sold 2,640 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the completion of the sale, the chief executive officer owned 199,539 shares in the company, valued at approximately $2,675,817.99. This trade represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 14.14% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on DYN shares. Raymond James Financial raised Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $31.00 to $35.00 in a research note on Monday, August 25th. Stifel Nicolaus dropped their price objective on shares of Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, July 31st. Lifesci Capital upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Oppenheimer lowered their target price on shares of Dyne Therapeutics from $13.00 to $11.00 and set a “market perform” rating for the company in a report on Wednesday. Finally, Royal Bank Of Canada upped their price target on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Four investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.93.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.